| Literature DB >> 34900706 |
Chia-Hui Chang1, Wen-Jeng Wu2,3,4, Hsiang-Ying Lee2,3,4, Chih-Hung Lin5,6, Chung-Tai Yue7,8, Yuan-Hong Jiang9, Yu-Khun Lee9, Kuan Hsun Huang10, Yao Chou Tsai11,12,13.
Abstract
PURPOSE: Pathology reviews for upper urinary tract cancer (UTUC) remained scarce in the literature. Here, we reported the interobserver variation among the review and local pathologies of featured histologic characteristics for UTUC.Entities:
Keywords: interobserver agreement; intratubular spread; pathology review; upper urinary tract cancer; variant histology
Year: 2021 PMID: 34900706 PMCID: PMC8655678 DOI: 10.3389/fonc.2021.757359
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Clinical features of upper tract urothelial cancer patients for pathology review.
| Variables | N (%) |
|---|---|
| Gender | |
| Male | 74 (48.1) |
| Female | 80 (51.9) |
| Age | |
| <70 | 67 (43.5) |
| ≥70 | 87 (56.5) |
| Location | |
| Renal pelvis | 87 (56.5) |
| Ureter | 60 (39.0) |
| Bladder cuff | 3 (1.9) |
| renal pelvis and ureter | 4 (2.6) |
| Surgical approach | |
| Nephroureterectomy | 146 (94.8) |
| Endoscopic management | 7 (4.5) |
| Segmental resection | 1 (0.6) |
Histopathologic characteristics recorded by the review and local pathologist.
| Variables | Local | Review | p-value | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Grade | |||||
| Low grade | 15 | (9.7) | 33 | (21.4) | 0.039 |
| High grade | 136 | (88.3) | 117 | (76.0) | |
| Dysplasia | 1 | (0.6) | 1 | (0.6) | |
| Not mentioned | 2 | (1.3) | 3 | (1.9) | |
| Configuration | |||||
| Papillary | 97 | (63.0) | 100 | (64.9) | 0.310 |
| Nodular | 26 | (16.9) | 31 | (20.1) | |
| Infiltrating | 16 | (10.4) | 17 | (11.0) | |
| Flattened | 5 | (3.2) | 3 | (1.9) | |
| Not mentioned | 10 | (6.5) | 3 | (1.9) | |
| Stromal invasion | |||||
| Invasive | 124 | (80.5) | 101 | (65.6) | 0.001 |
| Non-invasive | 23 | (14.9) | 50 | (32.5) | |
| Not mentioned | 7 | (4.5) | 3 | (1.9) | |
| Differentiation | |||||
| Pure urothelial | 142 | (92.2) | 107 | (69.5) | <0.001 |
| Squamous | 7 | (4.5) | 9 | (5.8) | |
| Sarcomatous | 0 | (0.0) | 10 | (6.5) | |
| Clear cell | 0 | (0.0) | 4 | (2.6) | |
| Nested variant | 0 | (0.0) | 6 | (3.9) | |
| Poorly differentiated | 2 | (1.3) | 3 | (1.9) | |
| Micropapillary | 1 | (0.6) | 3 | (1.9) | |
| Neuroendocrine | 0 | (0.0) | 1 | (0.6) | |
| Giant cell | 0 | (0.0) | 4 | (2.6) | |
| Mix type | 0 | (0.0) | 5 | (3.2) | |
| Not Available | 2 | (1.3) | 2 | (1.3) | |
| T stage | |||||
| Tx | 3 | (1.9) | 0 | (0.0) | 0.277 |
| Tis/Ta/T1 | 49 | (31.8) | 61 | (39.6) | |
| T2 | 27 | (17.5) | 20 | (13.0) | |
| T3 | 63 | (40.9) | 65 | (42.2) | |
| T4 | 7 | (4.5) | 4 | (2.6) | |
| Not mentioned | 5 | (3.2) | 4 | (2.6) | |
| Lymphovascular invasion | |||||
| Negative | 104 | (67.5) | 86 | (55.8) | 0.002 |
| Positive | 42 | (27.3) | 67 | (43.5) | |
| Not mentioned | 8 | (5.2) | 1 | (0.6) | |
| Peri-neural invasion | |||||
| Negative | 107 | (69.5) | 132 | (85.7) | <0.001 |
| Positive | 4 | (2.6) | 21 | (13.6) | |
| Not mentioned | 43 | (27.9) | 1 | (0.6) | |
| Margin status | |||||
| Free | 130 | (84.4) | 122 | (79.2) | 0.154 |
| Not free | 10 | (6.5) | 20 | (13.0) | |
| Not mentioned | 14 | (9.1) | 12 | (7.8) | |
| Intratubular spread | |||||
| Negative | Not Available | 118 | (76.6) | Not Available | |
| Positive | Not Available | 24 | (15.6) | ||
| Not mentioned | Not Available | 12 | (7.8) | ||
Comparative multivariate disease-free survival analysis of upper tract urothelial cancer.
| Multivariate analysis | Local | Review | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | ||||
| <70 | 1 | 1 | ||
| ≥70 | 3.229 (1.052, 9.913) | 0.040* | 7.856 (2.014, 30.643) | 0.003** |
| Gender | ||||
| Male | 1 | |||
| Female | 0.283 (0.101, 0.793) | 0.016* | ||
| Intratubular spread | ||||
| Negative | 1 | |||
| Positive | 11.592 (2.890, 46.494) | 0.001** | ||
| T stage | ||||
| Tis/Ta/T1/T2 | 1 | |||
| T3 | 1.434 (0.346, 5.946) | 0.620 | ||
| T4 | 0.036 (0.002, 0.840) | 0.039* | ||
| Margin status | ||||
| Free | 1 | 1 | ||
| Not free | 4.149 (1.410, 12.209) | 0.010* | 12.454 (3.142, 49.362) | <0.001** |
CI, confidence interval; HR, hazard ratio; DFS, disease-free survival.
* < 0.05. ** < 0.01.
Interobserver variation for pathological T stage.
| Review pathology | Original pathology (% | Total (%) | |||||
|---|---|---|---|---|---|---|---|
| Tx | Tis/Ta/T1 | T2 | T3 | T4 | Not mentioned | ||
| Tis/Ta/T1 | 3 (4.9) [100] | 41 (67.2) [83.7] | 7 (11.5) [25.9] | 7 (11.5) [11.1] | 0 (0.0) [0.0] | 3 (4.9) [60.0] | 61 (39.6) |
| T2 | 0 (0.0) [0.0] | 5 (25.0) [10.2] | 10 (50.0) [37.0] | 5 (25.0) [7.9] | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 20 (13.0) |
| T3 | 0 (0.0) [0.0] | 1 (1.5) [2.0] | 10 (15.4) [37.0] | 49 (75.4) [77.8] | 5 (7.7) [71.4] | 0 (0.0) [0.0] | 65 (42.2) |
| T4 | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 2 (50.0) [3.2] | 2 (50.0) [28.6] | 0 (0.0) [0.0] | 4 (2.6) |
| Not mentioned | 0 (0.0) [0.0] | 2 (50.0) [4.1] | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 2 (50.0) [40.0] | 4 (2.6) |
| Total | 3 (1.9) | 49 (31.8) | 27 (17.5) | 63 (40.9) | 7 (4.5) | 5 (3.2) | 154 (100) |
aPercentage of reviewed cases.
bPercentage of local cases.
Interobserver variation for tumor grade.
| Review pathology | Original pathology (% | Total (%) | |||
|---|---|---|---|---|---|
| Low grade | High grade | Dysplasia | Not mentioned | ||
| Low grade | 11 (33.3) [73.3] | 21 (63.6) [15.4] | 0 (0.0) [0.0] | 1(3.0) [50.0] | 33 (21.4) |
| High grade | 3 (2.6) [20.0] | 114 (97.4) [83.8] | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 117 (76.0) |
| Dysplasia | 0 (0.0) [0.0] | 0 (0.0) [0.0] | 1 (100) [100] | 0 (0.0) [0.0] | 1 (0.6) |
| Not mentioned | 1 (33.3) [6.7] | 1 (33.3) [0.7] | 0 (0.0) [0.0] | 1 (33.3) [50.0] | 3 (1.9) |
| Total | 15 (9.7) | 136 (88.3) | 1 (0.6) | 2 (1.3) | 154 (100) |
aPercentage of reviewed cases.
bPercentage of local cases.
Interobserver variation for surgical margin status.
| Review pathology | Original pathology (%a) [%b] | Total (%) | ||
|---|---|---|---|---|
| Free | Not free | Not mentioned | ||
| Free | 117 (95.9) [90.0] | 1 (0.8) [10.0] | 4 (3.3) [57.1] | 122 (83.0) |
| Not free | 10 (52.6) [7.7] | 9 (47.4) [90.0] | 0 (0.0) [0.0] | 19 (12.9) |
| Not mentioned | 3 (50.0) [2.3] | 0 (0.0) [0.0] | 3 (50.0) [42.9] | 6 (4.1) |
| Total | 130 (88.4) | 10 (6.8) | 7 (4.8) | 147 (100) |
aPercentage of reviewed cases.
bPercentage of local cases.
Figure 1Kaplan–Meier survival curves of disease-free survival stratified by original or review pathology in localized upper tract urothelial cancers (survival curves were created and analyzed by SPSS software version 26).
Figure 2Kaplan–Meier survival curves of disease-free survival stratified by original or review pathology in advanced upper tract urothelial cancers (survival curves were created and analyzed by SPSS software version 26).
Agreements between review and local pathology.
| Variables | Overall agreement (%) | Simple kappa (95% CI) |
|---|---|---|
| Grade | 82.5 | 0.431 (0.265, 0.596) |
| Stroma invasion | 76.6 | 0.447 (0.316, 0.577) |
| Lymphovascular invasion | 70.8 | 0.420 (0.288, 0.552) |
| Peri-neural invasion | 62.3 | 0.056 (-0.040, 0.152) |
| T stage | 67.5 | 0.520 (0.418, 0.622) |
| Margin status | 87.8 | 0.520 (0.419, 0.799) |
| Differentiation (pure urothelial or variant) | 72.1 | 0.168 (0.029, 0.307) |
Comparative univariate disease-free survival analysis of upper tract urothelial cancer patients according to local and review pathology.
| Univariate analysis | HR (95% CI) | p-value | Univariate analysis | Local | Review | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||||
| Gender | Intratubular spread | Not Available | |||||
| Male | 1 | Negative | 1 | ||||
| Female | 0.441 (0.196, 0.996) | 0.049* | Positive | 2.639 (1.075, 6.481) | 0.034* | ||
| Age | Grade | ||||||
| <70 | 1 | Low grade | 1 | 1 | |||
| ≥70 | 1.514 (0.686, 3.343) | 0.305 | High grade | 0.582 (0.218, 1.555) | 0.280 | 1.560 (0.534, 4.555) | 0.416 |
| Location | Dysplasia | 0.000 (0.000), | 0.981 | 0.000 (0.000), | 0.983 | ||
| Renal pelvis | 1 | Stroma invasion | |||||
| Ureter | 0.465 (0.183, 1.182) | 0.108 | Non-invasive | 1 | 1 | ||
| Bladder cuff | 4.223 (0.961, 18.553) | 0.056 | Invasive | 1.533 (0.455, 5.163) | 0.491 | 1.345 (0.561, 3.227) | 0.507 |
| Renal pelvis and ureter | 2.148 (0.281, 16.397) | 0.461 | Lymphovascular invasion | ||||
| Surgical approach | Negative | 1 | 1 | ||||
| Nephroureterectomy | 1 | Positive | 2.768 (1.173, 6.531) | 0.020* | 1.921 (0.862, 4.283) | 0.110 | |
| Endoscopic | 6.396 (2.492, 16.418) | <0.001** | Perineural invasion | Not Available | |||
| Segmental resection | 0.000 (0.000), | 0.982 | Negative | 1 | |||
| Positive | 3.443 (1.471, 8.059) | 0.004** | |||||
| T stage | |||||||
| Tis/Ta/T1/T2 | 1 | 1 | |||||
| T3 | 1.464 (0.588, 3.646) | 0.413 | 1.988 (0.868, 4.551) | 0.104 | |||
| T4 | 3.605 (1.079, 12.041) | 0.037* | 1.534 (0.193, 12.19) | 0.686 | |||
| Tx | 1.549 (0.191, 12.581) | 0.682 | |||||
| Margin status | |||||||
| Free | 1 | 1 | |||||
| Not free | 4.856 (1.680, 14.037) | 0.004** | 5.557 (2.110, 14.63) | 0.001** | |||
| Differentiation | |||||||
| Pure UC | 1 | 1 | |||||
| UC with variant | 4.259 (1.672, 10.846) | 0.002** | 1.772 (0.790, 3.973) | 0.165 | |||
CI, confidence interval; HR, hazard ratio; DFS, disease-free survival.
* < 0.05. ** < 0.01.